GAMP 5 A Risk Based Approach to A Risk-Based Approach to Compliant GxP Compliant GxP Computerized Systems
Shimadzu LC-2080 (Nexera) HPLC को ऑपरेट करने की Step-by-Step प्रक्रिया (हिंदी में)
PharmaText | www.pharmatext.co.in
यह गाइड फार्मास्यूटिकल QC लैब में नए कर्मचारियों (Freshers) को Shimadzu LC-2080 HPLC सिस्टम की कार्यप्रणाली समझाने के लिए तैयार की गई है। इसमें सिस्टम की तैयारी से लेकर सैंपल एनालिसिस, क्रोमैटोग्राम की समीक्षा और शटडाउन तक की प्रमुख प्रक्रियाएँ शामिल हैं।
1. HPLC सिस्टम का परिचय
Shimadzu LC-2080 HPLC सिस्टम के प्रमुख भाग निम्नलिखित हैं:
Mobile Phase Reservoir: मोबाइल फेज रखने के लिए।
Degasser: मोबाइल फेज में घुली गैसों को हटाने के लिए।
Pump: मोबाइल फेज को निर्धारित फ्लो रेट पर सिस्टम में प्रवाहित करने के लिए।
Autosampler: सैंपल को निर्धारित मात्रा में इंजेक्ट करने के लिए।
Column Oven: कॉलम का तापमान नियंत्रित रखने के लिए।
Detector: सैंपल के घटकों से प्राप्त सिग्नल को मापने के लिए।
LabSolutions Software: इंस्ट्रूमेंट कंट्रोल, डेटा एक्विजिशन और क्रोमैटोग्राम प्रोसेसिंग के लिए।
2. एनालिसिस से पहले आवश्यक तैयारी
सुनिश्चित करें कि HPLC सिस्टम और संबंधित उपकरण साफ-सुथरे हों।
मोबाइल फेज को अनुमोदित Analytical Method के अनुसार तैयार करें।
मोबाइल फेज को आवश्यकतानुसार उपयुक्त फिल्टर से फिल्टर और Degas करें।
सुनिश्चित करें कि मोबाइल फेज की बोतलों में पर्याप्त मात्रा उपलब्ध हो।
Waste Container की क्षमता और कनेक्शन जाँचें।
HPLC कॉलम का नाम, प्रकार, दिशा और कनेक्शन जाँचें।
सिस्टम के विद्युत कनेक्शन तथा आवश्यक यूटिलिटी की स्थिति जाँचें।
नमूनों, Reference Standards और आवश्यक Reagents की उपलब्धता सुनिश्चित करें।
महत्वपूर्ण: मोबाइल फेज की संरचना, pH, फिल्टर का प्रकार और कॉलम का चयन संबंधित अनुमोदित टेस्ट मेथड के अनुसार ही करें।
3. HPLC सिस्टम और LabSolutions Software शुरू करना
इंस्ट्रूमेंट को निर्धारित SOP के अनुसार चालू करें।
Pump, Autosampler, Column Oven और Detector की स्थिति जाँचें।
कंप्यूटर चालू करें और LabSolutions Software खोलें।
अधिकृत User ID से लॉगिन करें।
System Monitor में सभी संबंधित मॉड्यूल की स्थिति देखें।
किसी Error, Alarm या Communication Failure की स्थिति में समस्या का समाधान किए बिना एनालिसिस शुरू न करें।
लॉगिन क्रेडेंशियल केवल अधिकृत व्यक्ति द्वारा जारी किए गए होने चाहिए। किसी साझा या अनधिकृत अकाउंट का उपयोग न करें।
4. System Readiness Check
एनालिसिस से पहले निम्नलिखित बिंदुओं की जाँच करें:
Pump तथा Solvent Lines की स्थिति।
मोबाइल फेज की उपलब्धता और सही कनेक्शन।
कॉलम की सही स्थापना।
कॉलम ओवन का तापमान।
Detector का चयनित मोड और आवश्यक सेटिंग्स।
Autosampler की स्थिति तथा वायल की उपलब्धता।
System Pressure और किसी Leakage की स्थिति।
Detector Lamp तथा अन्य आवश्यक मॉड्यूल की स्थिति।
यदि सिस्टम में एयर बबल, असामान्य प्रेशर, लीकेज या कोई अन्य समस्या हो, तो संबंधित SOP के अनुसार सुधार करें।
5. Method बनाना या पहले से उपलब्ध Method खोलना
LabSolutions में संबंधित Instrument Control या Method सेटिंग्स खोलें।
यदि पहले से Approved Method उपलब्ध है, तो उसी Method को खोलें।
नई Method बनाने की आवश्यकता हो, तो अधिकृत प्रक्रिया के अनुसार नई Method बनाएँ।
Method में निर्धारित सभी पैरामीटर दर्ज करें।
Method को उचित नाम और Version के साथ सेव करें।
Method की समीक्षा और आवश्यक Approval सुनिश्चित करें।
ध्यान दें: किसी Approved Method में बिना अनुमति बदलाव न करें।
6. HPLC Method Parameters सेट करना
संबंधित Analytical Method के अनुसार निम्नलिखित पैरामीटर सेट करें:
Flow Rate: मोबाइल फेज प्रवाह की दर।
Mobile Phase Composition: मोबाइल फेज के घटकों का अनुपात।
Gradient Program: आवश्यकता होने पर समय के साथ मोबाइल फेज की संरचना में बदलाव।
Column Oven Temperature: कॉलम का निर्धारित तापमान।
Injection Volume: इंजेक्ट किए जाने वाले सैंपल की मात्रा।
Detector Settings: जैसे Wavelength या अन्य आवश्यक Detection Parameters।
Run Time: एनालिसिस की निर्धारित अवधि।
Data Acquisition Settings: डेटा रिकॉर्डिंग के लिए आवश्यक पैरामीटर।
Pressure Limit: इंस्ट्रूमेंट और कॉलम के लिए अनुमोदित सीमा।
सभी पैरामीटर संबंधित Approved Analytical Method से सत्यापित करें। केवल उदाहरण के आधार पर कोई सेटिंग लागू न करें।
7. सैंपल और स्टैंडर्ड तैयार करना
Approved Test Method के अनुसार सैंपल तैयार करें।
Reference Standard को निर्धारित प्रक्रिया के अनुसार तैयार करें।
आवश्यकतानुसार Dilution करें।
सैंपल और स्टैंडर्ड को निर्धारित फिल्टर से फिल्टर करें, यदि मेथड में आवश्यक हो।
तैयार घोल को उपयुक्त, साफ और लेबल किए हुए HPLC वायल में भरें।
प्रत्येक वायल पर Sample Name, Batch Number और अन्य आवश्यक पहचान दर्ज करें।
सैंपल की स्थिरता तथा निर्धारित Hold Time का पालन करें।
सैंपल तैयार करते समय दस्ताने और अन्य आवश्यक PPE का उपयोग करें।
8. Autosampler में वायल लोड करना और Sequence बनाना
तैयार वायल को निर्धारित Autosampler Positions में रखें।
वायल की स्थिति और Sequence Table में दर्ज Position का मिलान करें।
LabSolutions में Sequence या Batch Table खोलें।
Blank, Standard, System Suitability Samples और Test Samples को Approved Method के अनुसार क्रमबद्ध करें।
Sample Name, Vial Position, Injection Volume और Method की जाँच करें।
Sequence को सेव करें।
रन शुरू करने से पहले दूसरी बार सभी प्रविष्टियों की समीक्षा करें।
Sequence का क्रम संबंधित Analytical Method और प्रयोगशाला की SOP के अनुसार होना चाहिए।
9. HPLC रन शुरू करना और मॉनिटर करना
सुनिश्चित करें कि सिस्टम रन के लिए तैयार है।
आवश्यक Equilibration और System Suitability प्रक्रिया पूरी करें।
अधिकृत Sequence को शुरू करें।
रन के दौरान System Monitor और Real-Time Chromatogram देखें।
Pressure, Baseline, Retention Time और अन्य आवश्यक पैरामीटर पर ध्यान दें।
किसी असामान्य प्रेशर, Leakage, Error या अप्रत्याशित Chromatogram की स्थिति में SOP के अनुसार कार्रवाई करें।
सभी घटनाओं को निर्धारित लॉग या इलेक्ट्रॉनिक रिकॉर्ड में दर्ज करें।
चलते हुए रन को बिना उचित कारण और अधिकृत प्रक्रिया के बीच में न रोकें।
10. क्रोमैटोग्राम की समीक्षा और डेटा प्रोसेसिंग
रन पूरा होने के बाद:
संबंधित डेटा फाइल खोलें।
Chromatogram और Peak Integration की समीक्षा करें।
Retention Time, Peak Area और अन्य आवश्यक परिणामों की जाँच करें।
Blank, Standard और System Suitability के परिणामों का मूल्यांकन करें।
System Suitability Criteria पूरे होने की पुष्टि करें।
परिणामों की गणना Approved Method के अनुसार करें।
आवश्यक होने पर अधिकृत व्यक्ति से डेटा की समीक्षा करवाएँ।
रिपोर्ट निर्धारित प्रारूप में तैयार करें।
डेटा प्रोसेसिंग के दौरान किसी Peak को हटाने, Reintegration करने या Method में बदलाव करने की आवश्यकता हो, तो संबंधित SOP और Data Integrity Requirements का पालन करें।
महत्वपूर्ण: अस्वीकार्य परिणाम को छिपाएँ नहीं और बिना जाँच के सैंपल को दोबारा रन न करें। OOS/OOT परिणामों के लिए लागू SOP का पालन करें।
11. डेटा सेव करना और रिपोर्ट तैयार करना
Raw Data, Method, Sequence और संबंधित परिणामों को निर्धारित स्थान पर सुरक्षित रखें।
रिपोर्ट में Sample ID, Batch Number, Method Reference और आवश्यक परिणाम शामिल करें।
इलेक्ट्रॉनिक रिकॉर्ड की Audit Trail तथा अन्य आवश्यक रिकॉर्ड की समीक्षा करें।
डेटा का Backup और Archival स्वीकृत प्रक्रिया के अनुसार सुनिश्चित करें।
केवल अधिकृत व्यक्ति द्वारा रिपोर्ट की समीक्षा और Approval किया जाना चाहिए।
GMP प्रयोगशाला में डेटा को निर्धारित Retention Period तक सुरक्षित रखना आवश्यक है।
12. HPLC सिस्टम का शटडाउन
सुनिश्चित करें कि Sequence पूरी हो गई है और कोई रन सक्रिय नहीं है।
कॉलम को संबंधित Method और Column Manufacturer के निर्देशों के अनुसार Flush करें।
यदि मोबाइल फेज में Buffer या Salt मौजूद है, तो कॉलम और सिस्टम को अनुमोदित प्रक्रिया के अनुसार उपयुक्त विलायक से Flush करें।
Pump Flow को संबंधित SOP के अनुसार कम करें और बंद करें।
Detector तथा अन्य मॉड्यूल को निर्धारित प्रक्रिया के अनुसार बंद करें।
LabSolutions से उचित तरीके से Logout करें।
सिस्टम की Power केवल तभी बंद करें जब संबंधित SOP इसकी अनुमति देती हो।
कॉलम को निर्धारित Storage Solvent और परिस्थितियों में सुरक्षित रखें।
मोबाइल फेज, Waste Container और सिस्टम की अंतिम स्थिति जाँचें।
उपयोग के बाद आवश्यक लॉगबुक और रिकॉर्ड अपडेट करें।
सावधानी: Buffer को कॉलम या सिस्टम में सूखने न दें। कॉलम की Storage Conditions हमेशा उसके निर्माता के निर्देशों और Approved SOP के अनुसार रखें।
13. नए कर्मचारियों के लिए महत्वपूर्ण सावधानियाँ
HPLC को केवल प्रशिक्षित और अधिकृत पर्यवेक्षण में ऑपरेट करना सीखें।
प्रत्येक एनालिसिस के लिए Approved Analytical Method का उपयोग करें।
मोबाइल फेज और सैंपल तैयार करते समय सुरक्षा नियमों का पालन करें।
प्रेशर लिमिट से अधिक दबाव या असामान्य Leakage को नजरअंदाज न करें।
कॉलम बदलने से पहले उसकी Compatibility और Flow Direction की पुष्टि करें।
किसी भी Error या असामान्य परिणाम को रिकॉर्ड करें।
Raw Data और Audit Trail के साथ छेड़छाड़ न करें।
Instrument Logbook और SOP का नियमित पालन करें।
निष्कर्ष
Shimadzu LC-2080 HPLC का सही संचालन केवल बटन दबाकर रन शुरू करने तक सीमित नहीं है। इसमें मोबाइल फेज की तैयारी, सिस्टम की उपयुक्तता, सही Method Parameters, सैंपल हैंडलिंग, System Suitability, डेटा समीक्षा और उचित शटडाउन सभी शामिल हैं।
यह गाइड प्रशिक्षण के लिए है। वास्तविक संचालन से पहले संबंधित Instrument Manual, Approved Analytical Method और प्रयोगशाला की वर्तमान SOP का पालन करना अनिवार्य है।
PharmaText – Pharma Professionals के लिए विश्वसनीय शैक्षणिक प्लेटफॉर्म
🌐 https://www.pharmatext.co.in
#PharmaText #Shimadzu #LC2080 #Nexera #HPLC #HPLCTraining #HPLCOperation #HPLCAnalysis #LabSolutions #PharmaceuticalIndustry #PharmaceuticalQC #QualityControl #AnalyticalChemistry #PharmaEducation #GMP #DataIntegrity #Chromatography #PharmaProfessionals #QCAnalyst #FreshersTraining
The Digital Shadow of a Pharmaceutical Batch: How Regulators Can Reconstruct What Really Happened Inside a Pharma Factory
The batch record may not tell the whole story
Imagine that a pharmaceutical company has manufactured a batch of tablets.
The Batch Manufacturing Record is complete.
The Batch Packaging Record is complete.
QC results are within specification.
The QA review is satisfactory.
The batch is released.
At first glance, everything appears normal.
But what if someone asks a much more difficult question?
“Can you prove exactly what happened during the manufacture and testing of this batch?”
That question changes the investigation completely.
A pharmaceutical batch does not generate only a BMR or BPR. During its journey through a manufacturing facility, it can generate hundreds or thousands of pieces of information.
Some are on paper.
Some are electronic.
Some are stored in laboratory systems.
Some are stored in ERP or manufacturing systems.
Some exist in equipment records.
Some exist in audit trails.
Some may even exist in access-control or environmental monitoring systems.
Together, these records can create what we can describe as the:
“Digital Shadow” of a Pharmaceutical Batch
The term “digital shadow” is useful for understanding the interconnected information surrounding a batch. It is not a regulatory term by itself.
The important regulatory concept is data integrity.
FDA states that data used to support CGMP decisions must be reliable and accurate and recommends risk-based strategies for preventing and detecting data-integrity problems.
WHO guidance similarly emphasizes audit trails and the ability to reconstruct relevant GxP activities through reliable electronic records and metadata.
What exactly is the digital shadow of a batch?
Consider a typical pharmaceutical batch.
It may pass through:
Raw Material Receipt
↓
Sampling
↓
QC Testing
↓
Dispensing
↓
Manufacturing
↓
In-Process Testing
↓
Bulk Storage
↓
Packaging
↓
Finished Product Testing
↓
QA Review
↓
Batch Release
↓
Warehouse
↓
Distribution
At almost every stage, information is created.
For example:
| Area | Examples of information generated |
|---|---|
| Warehouse | Receipt, quantity, material status, movement |
| QC | Sampling, testing, results, raw data |
| Dispensing | Weighing, operator, material quantity |
| Production | Process parameters, equipment usage |
| IPQA | Line clearance, IPC, observations |
| Engineering | Calibration, maintenance, breakdown |
| HVAC | Temperature, RH, differential pressure |
| LIMS | Sample registration, results, approvals |
| HPLC/GC/UV | Raw analytical data and metadata |
| ERP/SAP | Material and inventory transactions |
| MES | Electronic manufacturing information |
| BMS/SCADA | Environmental/process information |
| Access Control | Entry/exit records |
| DMS | Controlled documents and approvals |
| Backup systems | Preservation and recovery of electronic information |
| QA | Deviations, OOS, CAPA, change controls |
The BMR is therefore only one part of the evidence surrounding a batch.
Why this matters during a regulatory inspection
An inspector may not simply ask:
“Show me the BMR.”
The investigation may go much further.
For example:
Who performed the activity?
When was it actually performed?
Which equipment was used?
Was the equipment available and released for use?
Was it calibrated?
Was cleaning completed?
What happened in the laboratory?
Were there repeated injections?
Were electronic records modified?
Was the audit trail reviewed?
Were original data retained?
Who approved the result?
Can the company reconstruct the sequence of events?
This is why modern pharmaceutical data integrity is not simply about keeping documents safely.
It is about maintaining trustworthy evidence throughout the data lifecycle.
A pharmaceutical batch leaves many fingerprints
A useful way of thinking about a batch is to imagine that every important activity leaves a fingerprint.
For example:
BMR fingerprint
What was documented?
Equipment fingerprint
Which equipment was used and when?
Laboratory fingerprint
What analytical data were generated?
Audit-trail fingerprint
What was created, changed or deleted?
ERP fingerprint
What material transactions occurred?
Access-control fingerprint
Who entered the relevant area?
Environmental fingerprint
What were the relevant environmental conditions?
QA fingerprint
What deviations, investigations and approvals occurred?
None of these records should automatically be assumed to be infallible.
But together, appropriately controlled records can help investigators understand what actually happened.
The first question: Who actually performed the activity?
Suppose a BMR contains an entry stating:
“Granulation completed at 14:30.”
The document contains an operator signature.
Is that enough?
Not necessarily.
Depending on the activity and systems involved, an investigation may also consider:
operator authorization
training status
electronic user account
equipment login
access-control record
electronic batch record
equipment activity
contemporaneous observations
related documentation
This does not mean that access-control records automatically prove who performed a GMP activity.
They are simply another potentially relevant piece of evidence.
A discrepancy should trigger investigation—not an automatic conclusion.
The second question: Was the equipment actually available?
Imagine that a BMR states:
Equipment XYZ-101 used from 09:00 to 11:00.
The investigator may want to understand:
Was XYZ-101 available?
Was it cleaned?
Was cleaning verified?
Was it calibrated?
Was maintenance ongoing?
Was another batch using the equipment?
Was the equipment released?
Does its electronic record show activity during the same period?
This is where cross-system review becomes powerful.
A record may look correct when viewed alone.
It may look very different when compared with other relevant records.
The third question: What happened inside the laboratory?
Laboratory data are particularly important because a final result may represent only the end product of a much larger data set.
Consider an HPLC analysis.
The final report might show:
Assay: 99.2% — Complies
But the underlying analytical record may include:
Sample identification
Sequence
Injection information
Chromatographic data
Method
Processing method
System suitability
Integration parameters
Reprocessing
User information
Date/time information
Audit trail
Electronic approval
Therefore:
The final printed report is not necessarily the complete analytical story.
FDA specifically addresses audit trails, access controls, original electronic records and laboratory chromatography data in its data-integrity guidance.
The HPLC example that every QA and QC professional should understand
Imagine an analyst performs an HPLC test.
The first processing produces:
Result: 96.8%
The analyst then reprocesses the chromatogram.
The final report shows:
Result: 98.4%
Now the question is not simply:
“Why did the result change?”
The investigation should ask:
Why was the data reprocessed?
Who performed the reprocessing?
What processing parameter changed?
Was the change scientifically justified?
Was the original data retained?
Is the audit trail available?
Was the reprocessing authorized?
Was the reason documented?
Was the final result independently reviewed?
Does the final conclusion remain scientifically valid?
Reprocessing itself is not automatically evidence of wrongdoing.
The critical issue is whether the activity is controlled, attributable, scientifically justified and traceable.
The fourth question: What was happening inside the manufacturing area?
Suppose the BMR records:
Granulation temperature: 55°C
That may be a legitimate recorded process value.
But suppose the manufacturing process is also monitored electronically.
The electronic system may contain:
55°C → 56°C → 58°C → 61°C → 59°C → 55°C
Now the investigator can ask:
How long was the temperature outside the target?
Was an alarm generated?
Was an intervention performed?
Was the excursion documented?
Was the event assessed?
Did it affect product quality?
Was a deviation raised?
The objective is not to make electronic data “win” over the BMR.
The objective is to understand the complete event.
The fifth question: What does the access-control system tell us?
This is one of the most interesting areas of modern pharmaceutical investigations.
Imagine that a critical manufacturing activity is documented at:
02:15 AM
But the relevant operator's access-control record shows entry at:
02:42 AM
Should the company immediately conclude that the BMR was falsified?
No.
There may be several legitimate explanations:
Different access point
System-clock difference
Delayed documentation
Preparation performed earlier
Another authorized person performed part of the activity
Access-control configuration
Emergency access
System malfunction
Documentation error
The discrepancy should therefore be investigated.
A discrepancy is an investigation trigger—not an automatic conclusion.
The sixth question: What happened to the original data?
This is one of the most important questions in data integrity.
Consider:
Original data → Processing → Review → Approval → Final report
If the original data are not retained, the investigator may have difficulty establishing what happened.
Indian regulatory material defines raw data broadly and includes laboratory records, software, computer printouts, spectral charts and automated-equipment data among the types of information that may constitute raw data. It also requires preservation of original entries and audit trails for automated systems.
Therefore, a pharmaceutical company's data-management strategy must consider more than simply saving a PDF report.
“The report” is not always “the data”
This distinction deserves special attention.
Imagine a computerized analytical system.
The company retains:
Final PDF report
But the original electronic data, metadata and relevant audit-trail information are not adequately retained or accessible.
The PDF may show the final result.
But it may not provide the same ability to reconstruct:
what happened before the final result,
what processing occurred,
whether changes were made,
who made them,
when they were made,
why they were made.
That is why original electronic records and appropriate metadata can be critical.
The audit trail: a window into the history of electronic data
An audit trail can record relevant actions affecting electronic records.
Depending on system design, it may help establish:
Who
What
When
Where applicable, why
For example:
User A created a record at 09:12.
User A modified a parameter at 09:18.
User B reviewed the record at 10:02.
User C approved the record at 11:15.
The exact information captured depends on the system and configuration.
WHO's current data-integrity guidance states that relevant GxP audit trails should be enabled and remain enabled, with periodic verification that they remain active throughout the data lifecycle.
The audit trail should not be treated as an IT-only issue
This is an important organizational point.
Audit trails are sometimes treated as something belonging exclusively to:
IT / CSV / Computerized Systems Validation
That is incomplete.
An audit trail may contain information directly relevant to:
QC
QA
Production
Engineering
Regulatory Affairs
Data Integrity
Laboratory Management
The business owner of the system and the quality function have important roles in determining which audit-trail information is relevant and how it should be reviewed.
WHO material also emphasizes risk-based review of relevant audit-trail information rather than indiscriminate review of every system activity.
When two systems tell different stories
Here is a fictional example.
| Record | Time |
|---|---|
| BMR | 08:00 |
| Equipment record | 08:14 |
| Access control | 08:19 |
| LIMS | 08:23 |
| IPC record | 08:05 |
| Electronic batch record | 08:16 |
Which one is correct?
The answer should not be selected simply because one system appears more sophisticated.
The investigation should first understand:
How each timestamp is generated
Whether system clocks are synchronized
Whether time zones or daylight-saving settings apply
Whether entries are contemporaneous
Whether records are manually entered
Whether automatic records are generated at a different process stage
Whether there was a system configuration issue
Whether a deviation exists
Whether product quality was affected
Only after understanding the data-generating processes can the discrepancy be properly assessed.
A fictional GMP investigation: The batch that looked perfect
Let's consider a hypothetical batch.
Product
ABC-500 Tablets
Batch
ABC260915
Manufacturing date
15 September 2026
The batch was manufactured.
QC results passed.
QA reviewed the documentation.
The batch was released.
Nothing appeared unusual.
Later, an investigation was initiated because of an unrelated quality complaint.
The investigation team decided to review the complete batch history.
Finding 1 — BMR
Compression started:
14:00
Finding 2 — Equipment record
Machine activity began:
14:37
Finding 3 — Access control
Operator entered the area:
14:31
Finding 4 — IPC record
First IPC sample:
14:10
Finding 5 — Electronic process record
First relevant electronic record:
14:38
Now there is a question:
What actually happened between 14:00 and 14:38?
The investigation team should not immediately accuse anyone.
Instead, they should reconstruct the sequence.
Perhaps:
14:00 was the preparation/start time entered in the BMR.
14:10 represented sample preparation rather than actual compression.
14:31 was the operator's entry through a particular access point.
14:37 was machine activation.
14:38 was the first automatically captured process event.
The apparent contradiction may disappear once the data-generating processes are understood.
Or it may reveal a genuine documentation problem.
That is precisely why investigation is required.
A batch has a data chain
A useful way to understand pharmaceutical data integrity is to think in terms of a data chain:
Material
↓
Activity
↓
Record
↓
Review
↓
Approval
↓
Decision
If something goes wrong at any point, the reliability of the final decision may be affected.
For example:
Raw material → Testing → Dispensing → Manufacturing → IPC → QC → QA → Release
Every arrow represents a potential information transfer.
Therefore, data integrity is not simply about individual records.
It is about the integrity of the entire chain.
Where can data-integrity risks hide?
1. Paper records
Potential risks include:
Backdating
Uncontrolled corrections
Missing entries
Unclear entries
Blank spaces
Uncontrolled forms
2. Laboratory systems
Potential risks include:
Shared accounts
Unauthorized reprocessing
Deleted data
Uncontrolled processing methods
Inadequate audit-trail review
3. Manufacturing systems
Potential risks include:
Changed process parameters
Unrecorded interventions
Incomplete electronic records
Inappropriate user access
4. ERP systems
Potential risks include:
Backdated transactions
Stock adjustments
Unauthorized changes
Incorrect master data
5. LIMS
Potential risks include:
Result modification
Sample manipulation
Inadequate approval controls
Inadequate audit-trail review
6. Access-control systems
Potential risks include:
Shared credentials
Incorrect user configuration
Time synchronization problems
Inadequate record retention
7. Backup systems
Potential risks include:
Failed backups
Incomplete backups
Inability to restore historical data
Inadequate retention
Why ALCOA+ is only the beginning
Most pharmaceutical professionals know the ALCOA+ principles.
Attributable
Legible
Contemporaneous
Original
Accurate
And additional principles such as:
Complete
Consistent
Enduring
Available
These principles remain fundamental.
But during an investigation, another question becomes extremely important:
Can the sequence of events be reconstructed?
For example:
Who → Did what → When → On which system → Using which data → What changed → Why → Who reviewed it → What decision followed?
That is where data governance, metadata and audit trails become particularly valuable.
What should a pharmaceutical company review during a batch investigation?
A practical investigation may need to consider multiple evidence sources.
Manufacturing
☐ BMR/BPR
☐ Equipment usage
☐ Cleaning records
☐ Calibration status
☐ Maintenance records
☐ IPC records
☐ Environmental records
Laboratory
☐ Raw data
☐ Chromatograms
☐ Sequences
☐ Audit trails
☐ Reprocessing
☐ Invalidated data
☐ Electronic signatures
Computerized Systems
☐ User access
☐ Privileged accounts
☐ Audit-trail status
☐ System clocks
☐ Backup availability
☐ Data restoration
Materials
☐ Receipt records
☐ Sampling records
☐ Dispensing records
☐ Material movement
☐ Reconciliation
Personnel
☐ Training
☐ Authorization
☐ Access records
☐ Interviews
Quality System
☐ Deviations
☐ OOS/OOT
☐ CAPA
☐ Change controls
☐ Previous investigations
The role of IT in modern GMP investigations
The traditional view was:
IT keeps the computers running.
Modern pharmaceutical manufacturing requires a much broader view.
IT/CSV teams may become critical participants in investigations involving:
LIMS
ERP/SAP
MES
CDS
HPLC/GC systems
Document management
Backup systems
User management
Audit trails
Network infrastructure
Time synchronization
Data archival
Disaster recovery
However, IT should not independently decide the quality significance of a data discrepancy.
That assessment normally requires appropriate involvement from the system owner, QA and relevant technical functions.
The strongest investigation is therefore cross-functional.
The role of QA
QA has a particularly important role because the question is ultimately not only:
“What happened?”
but also:
“What is the quality impact, and can the company demonstrate control?”
QA may need to evaluate:
Data reliability
Product impact
Patient risk
Scope
Historical batches
Related products
Similar systems
Deviations
CAPA
Regulatory reporting implications
Effectiveness of corrective actions
A recent FDA warning letter issued in July 2026 illustrates the seriousness with which data-integrity deficiencies can be treated. FDA called for a comprehensive investigation into the extent of inaccuracies across laboratories, manufacturing operations and systems, including omissions, alterations, deletions and non-contemporaneous record completion.
That is a useful reminder that a data-integrity investigation may need to go far beyond one document or one batch.
The most dangerous assumption in a pharmaceutical investigation
One of the most dangerous assumptions is:
“The BMR is complete, therefore the batch history is complete.”
That conclusion may be too simplistic.
The BMR is extremely important.
But depending on the manufacturing process and computerized systems involved, the overall evidence may also include:
BMR + BPR + Raw Data + Audit Trails + Equipment Records + Material Records + Environmental Data + Electronic Records + Quality Records
The goal is not to collect every piece of information in existence.
The goal is to identify the relevant evidence necessary to reconstruct and evaluate the event.
How pharmaceutical companies can strengthen their “digital shadow”
Companies can take several practical steps.
1. Map critical data flows
For each critical process, identify:
Where is data created?
Where is it processed?
Where is it stored?
Who can modify it?
Who reviews it?
How is it backed up?
How is it retrieved?
2. Control user access
Use unique user accounts wherever required.
Avoid uncontrolled shared accounts.
3. Protect audit trails
Audit trails should be appropriately configured, protected and reviewed according to system risk.
4. Synchronize system clocks
Time discrepancies can complicate investigations.
5. Protect original records
Do not treat a final PDF or printout as automatically equivalent to the complete original electronic record.
6. Validate computerized systems appropriately
Systems should remain in a validated state through their lifecycle.
7. Test backup and restoration
A backup that cannot be restored when required is not an adequate practical safeguard.
8. Train users
Training should address not only “how to operate the system” but also:
Why the data matter.
9. Conduct periodic data-integrity assessments
Do not wait for an inspection or major deviation.
The future of pharmaceutical inspections
The pharmaceutical industry is becoming increasingly digital.
Manufacturing facilities now use combinations of:
ERP
LIMS
MES
SCADA
BMS
CDS
Electronic Batch Records
Document Management Systems
Serialization
Access Control
Cloud/Backup Infrastructure
As these systems become interconnected, regulatory inspections are likely to increasingly involve questions about the relationship between systems and the integrity of the underlying data.
The question may no longer simply be:
“Show me the document.”
It may increasingly become:
“Show me the evidence that allows you to reconstruct what happened.”
The real lesson: Every batch has a story
Every pharmaceutical batch has a story.
The BMR tells part of that story.
The QC report tells another part.
The laboratory raw data tell another.
The equipment records tell another.
The audit trail tells another.
The material records tell another.
The environmental monitoring system may tell another.
The quality system tells another.
The real challenge is determining whether all these pieces form a consistent, reliable and scientifically defensible story.
That is the true importance of the pharmaceutical batch's digital shadow.
A batch may leave the factory as a physical product.
But it leaves behind a much larger trail of information.
And during a serious investigation, that information can become just as important as the product itself.
Frequently Asked Questions
What is a pharmaceutical batch investigation?
A pharmaceutical batch investigation is a structured examination of manufacturing, testing, documentation, computerized-system data and other relevant evidence to determine what happened and whether product quality, patient safety or data integrity may have been affected.
What is the digital shadow of a pharmaceutical batch?
“Digital shadow” is a descriptive term for the electronic and documentary information generated around a batch. It can include laboratory data, manufacturing data, audit trails, ERP transactions, equipment records, environmental data and other relevant information.
What is an audit trail in pharmaceutical manufacturing?
An audit trail is a record associated with actions affecting electronic data, such as creation, modification or deletion. It can help reconstruct the history of relevant electronic records.
Can HPLC audit trails be reviewed during a GMP investigation?
Yes. Where applicable, audit trails associated with chromatography data systems can help assess the history of analytical data, including processing activities and changes.
Does a discrepancy between two systems automatically mean data falsification?
No. A discrepancy should be investigated. Differences can arise from system design, timestamp configuration, workflow, manual documentation, synchronization issues or other legitimate causes.
Is data integrity only the responsibility of QC?
No. Data-integrity responsibilities can extend across QA, QC, Production, Engineering, Warehouse, IT, CSV, Regulatory Affairs and other functions depending on the data lifecycle.
Why are original electronic records important?
Original records and relevant metadata may contain information that cannot be reconstructed from a final report alone. They can be important for demonstrating how data were generated, processed, reviewed and approved.
Conclusion
The modern pharmaceutical factory is no longer just a collection of machines, laboratories and paper records.
It is a connected information environment.
A single pharmaceutical batch can generate thousands of pieces of information across multiple systems.
That creates a digital shadow.
Understanding that shadow is becoming increasingly important for:
QA professionals
QC professionals
Production teams
IT and CSV teams
Data-integrity professionals
Regulatory Affairs teams
Pharmaceutical management
and, ultimately, patient safety.
The most important question is therefore not simply:
“Is the batch record complete?”
It is:
“Can the evidence demonstrate what actually happened?”
That is the real test of data integrity.
Regulatory References
This article is intended for educational purposes. Pharmaceutical companies should always assess requirements against the regulations, guidance and approved procedures applicable to their operations.
Key reference documents include:
US FDA — Data Integrity and Compliance With Drug CGMP: Questions and Answers
WHO — Guideline on Data Integrity
CDSCO — Drugs Rules, 1945 / applicable Indian GMP requirements
Applicable company SOPs, data-integrity policies and computerized-system procedures.
Build Greater Confidence in E&L Screening-USP Technical Guide
How confident are you in your E&L screening?
Non-targeted screening must detect a broad and largely unknown range of organic extractables and leachable. Differences in instruments, methods, and laboratory workflows can make demonstrating consistent performance difficult.
This USP Technical Guide explores how standardized system suitability mixtures can help laboratories verify critical performance attributes, including chromatographic range, sensitivity, specificity, precision, and system stability.
Kent's Comparative Repertory of The Homoeopathic Materia Medica
Kent’s Comparative Repertory of Homoeopathic Materia Medica is an important work by Dr. Dockx & Dr. Kokelenberg. This work aims to help the users of Kent’s Homoeopathic Repertory in grasping the very essence of the book- understanding the meaning of each rubric, completing each rubric and gathering all the additional rubrics and remedies and cross references by a variety of reliable authors- the tasks essential to convert patients’ symptoms in the language of Kent’s Repertory. Therefore, this book is a helping hand for the physicians and students alike to overcome the problem of understanding the exact meaning of each rubric and to differentiate amongst the closely related ones such as 'Abandonned and Forsaken'
KEY FEATURES:
Explanation of meanings of each rubric along with their cross references
Explanation of the important remedies including the, additions from other renowned repertories and materia medica
Additional information such as differential diagnosis for the remedies, clinical tips for various conditions and the dosage of various remedies, sources of additional remedies etc.
Thorough explanation of the Mind chapter of Kent’s Repertory which is very important for Homeopathic treatment of diseases.
A bonus to all readers of this book- The comparison of the rubrics in Kent's repertory with the similar ones under other repertories such as Boericke pocket book, BBCR, Barthel's repertory etc which have been extensively presented in this book- A benefit to both students and practitioners of homeopathy.
36 references from various important repertories and materia medica: Kent’s Repertory of Homoeopathic Materia Medica with word and thumb index, Kent’s Lectures in Materia Medica with New Remedies, Knerr’s Repertory of Hering’s Guiding Symptoms, Boger’s Boenninghausens’s Characteristics and Materia Medica, Jahr’s Repertory.
Pharma Times IPA: September 2026
We’re delighted to present the September 2026 Edition of Pharma Times.
Centered on the theme Rational Use of Medicines, this edition brings together insights from distinguished global experts across India, Australia, Malaysia, Kazakhstan, and Moldova to address the critical need for purposeful prescribing, robust clinical governance, and holistic patient care.
Here's what awaits you in this issue:
1. Rational Use of Medicines: “Prescribe with Purpose, Use with Care, Smart Choices for a Healthy Future”: A foundational overview emphasizing the clinical imperatives of judicious drug prescribing and responsible medication use.
2. Improving Clinical Protocols and the List of Essential Medicines for Children: International Experience and Current Approaches: An examination of global strategies and evidence-based frameworks designed to optimize pediatric clinical practice guidelines.
3. Prescribe with Purpose, Use with Care: Why We Teach Drugs But Never Teach Care: An eye-opening article, especially for the next generation of prescribers, that strongly advocates for rational use of medicines.
4. Nutraceuticals and Their Potential Health Benefits: Appropriate Use, Common Irrationalities and Patient-Safety Safeguards: An evaluation of the evidence behind dietary supplements, addressing improper usage trends, safety concerns, and the need for evidence-backed guidance.
5. Responsibly Using Medicines in All Sectors for Sustainability!: An exploration of multi-sectoral approaches to sustainable pharmaceutical consumption, highlighting environmental stewardship and antimicrobial management.
6. Sustaining India’s Pharmaceutical Leadership: From the Pharmacy of the World to Patient-Centered Pharmaceutical Care : A strategic analysis on transitioning from volume-driven drug manufacturing to value-added, patient-focused healthcare delivery.
7. Transforming Pharmacy Education: From Traditional Learning to NEP-Aligned, Future-Ready Education: A forward-looking review of curricular reform, aligning pharmaceutical pedagogy with modern clinical demands and national educational policies.
8. Enduring Legacy of Acharya P. C. Ray: An Architect of Indian Chemical & Pharmaceutical Renaissance: A historical retrospective honoring the profound vision, industrial spirit, and scientific contributions of the 'Father of Indian Chemistry'.
9. Five Realities That Deserve Immediate Attention Before Prioritizing the Implementation of NEP 2020 at the Grassroots Level: A pragmatic critique identifying key operational and structural challenges in executing educational reforms within frontline institutions.
We are sure you would find this compilation interesting and informative!
IPEC Qualification of Excipients for Use in Pharmaceuticals – Guide & Checklist | Version 3, 2026
Pharmaceutical excipients play a critical role in the quality, performance, stability, safety, and manufacturability of medicinal products. Proper qualification of excipients and their suppliers is therefore an important element of pharmaceutical quality management.
The IPEC Federation’s “Qualification of Excipients for Use in Pharmaceuticals: Guide & Checklist – Version 3, 2026” provides an updated framework for excipient suppliers and pharmaceutical manufacturers to understand key expectations associated with the qualification and use of pharmaceutical excipients.
This comprehensive guide covers the excipient qualification process, including:
- Purpose, scope and principles of excipient qualification
- General guidance on excipient manufacture, regulation and controls
- Excipient functionality and intended use
- Regulatory and safety assessment
- Novel excipients and precedence of use
- Pharmacopeial requirements
- Excipient DMFs, CEPs and regulatory dossiers
- Manufacturing, packaging and process validation
- Test methods, specifications and stability
- Excipient development and specification processes
- Performance indicators and consistency control
- Product information and confidential information
- Excipient selection criteria
- Compatibility and performance considerations
- Supply and regulatory considerations
- Excipient manufacturer qualification
- Annex A – Qualification Checklist for practical evaluation of excipients and excipient suppliers.
The guide emphasizes the relationship between excipient suppliers and pharmaceutical excipient users, with the objective of establishing appropriate quality, technical, regulatory and communication controls. It also provides practical considerations for assessing excipients according to their intended application, route of administration, quality attributes and performance requirements.
For pharmaceutical manufacturers, QA, QC, Regulatory Affairs, R&D, Procurement, Technical Services and Supplier Quality teams, this guide can serve as a useful reference when developing or reviewing an excipient qualification programme.
Important Note
The IPEC document states that it is voluntary guidance and not a regulatory requirement, and that applicable national/regional regulatory requirements should be reviewed separately.
Reference: International Pharmaceutical Excipients Council (IPEC) Federation – Version 3, 2026.
Explore more pharmaceutical quality, GMP and regulatory resources:
PharmaText® – www.pharmatext.co.in
Download Free Here
#PharmaText #IPEC #PharmaceuticalExcipients #ExcipientQualification #PharmaceuticalIndustry #PharmaceuticalQuality #GMP #GDP #QualityAssurance #QualityControl #RegulatoryAffairs #PharmaceuticalManufacturing #SupplierQualification #VendorQualification #PharmaRegulatory #PharmaCompliance #ICH #Pharmacopoeia #DrugDevelopment #PharmaceuticalRAndD #GxP #PharmaProfessionals #PharmaGuidelines #PharmaIndustry #ExcipientQuality
Subscribe to:
Posts (Atom)